Read Larry Connors' blog – Short Term Trading Strategies
Now, Pfizer is looking to Gelfoam, a product that helps control bleeding, to boost its sales with a new kit that combines a sponge form of the product with a drug made by Baxter Healthcare Corp. for use in hospitals to control bleeding during surgery.
The federal Food and Drug Administration approved the Gelfoam Plus Hemostatis Kit last year for hospital use.
The product already has triggered "a slight uptick in sales," said Matt Abel, manager and team leader for Pfizer's Gelfoam operations.
Pfizer's Kalamazoo plant, where Gelfoam is made, hopes to make 4 million of the products this year. It comes in sponge and powder form or in thin-film strips used in dentistry. They generated $40 million in domestic sales last year, and another $13 million globally, according to company figures.
"Gelfoam is one of our established products," said Rick Chambers, a Pfizer spokesman. "It's not one of our top-selling products, a Lipitor, but it's added a very steady revenue stream over the years. Our expectation is it will continue to grow."
Gelfoam is the leading topical product to control bleeding, with 14% of the market. It ranks second, behind a Johnson & Johnson item, in all bleeding-control products, he said.
Pfizer invested $12 million to renovate the plant several years ago. The company updated its air-handling, gowning and other measures to improve the sterility of the manufacturing, along with other steps to reduce repetitive strain injury.
About 30 employees produce Gelfoam. In a process compared to the way marshmallows are made, it is manufactured in long, white sterile biodegradable blocks then cut into bricks, before the sheets are put in a slicing machine, followed by a series of moisture-eliminating and sterile paper-packaging steps.
The process takes nearly a month because part of the packaging and inspection is done by hand.
Contact PATRICIA ANSTETT at 313-222-5021 or panstett@freepress.com.
To see more of the Detroit Free Press, or to subscribe to the newspaper, go to http://www.freep.com Copyright (c) 2008, Detroit Free Press Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
